News, Resources and Publications from Canopy Care - Canopy

Articles

Clinical

Canopy to be Highlighted at ASCO 2025 Quality Care Symposium

Study shows potential of the Canopy Remote Therapeutic Monitoring Platform to enable proactive adherence and toxicity management in patients receiving oral anti-cancer medications New York, New York - Canopy, the leading Enterprise AI Platform for Oncology, today announced findings on the potential for EHR-integrated Remote Therapeutic Monitoring (RTM) to enable practices with medically integrated pharmacies (MIPs) to meet or exceed ASCO/NCODA standards for oral anti-cancer medication (OAM). While traditional approaches rely on phone-based OAM management, the Canopy RTM platform provides an easily scalable, technology-enhanced approach.

October 9, 2025

Clinical

Remote Therapeutic Monitoring to Support Adoption of Bispecific Antibodies Therapy in Community Practices

June 16, 2025

Clinical

Canopy to be Highlighted in Two Studies at ASCO 2025 Annual Meeting

Research shows ability to surface real-world, regimen-specific symptom trends and highlight potential in-class differences using the Canopy Remote Therapeutic Monitoring Platform

May 27, 2025

Texas Oncology to Roll Out Canopy

Featured in: AJMC Evidence Based Oncology | Volume 31 | Issue 04

March 18, 2025

Clinical

Canopy Named to the New York Digital Health 100 for Second Consecutive Year

DH100 recognizes standout companies that have helped make New York the capital of healthcare innovation

February 6, 2025

Canopy to be Highlighted in Two Studies at ASH 2024

Research Shows Potential to Improve Time on Treatment and Detection of High-Risk Toxicities for Blood Cancer Patients Using the Canopy Continuous Care Platform New York – Canopy, the first Continuous Care Platform for oncology, today announced findings from two studies demonstrating the clinical impact of EHR-integrated Remote Therapeutic Monitoring for patients with various hematologic malignancies. These studies demonstrate the potential of the Canopy Platform to increase time on treatment and improve detection of high-risk toxicities in patients across a variety of therapies, including bispecific antibodies.

November 12, 2024